CategorySurgical robots
Overview
Sentante is a Vilnius-based medical robotics company developing an endovascular robotic platform with haptic force feedback and real-time guidance for remote vascular interventions. The first endovascular robot to complete an entire procedure in a clinical trial (ESSENTIAL, NCT06537947). Backed by €6M seed funding from Practica Capital and EIC Fund.
Reality check
CE mark (company-claimed)
Secured CE mark approval on May 20 2026 for its endovascular robotic platform, enabling marketing and sales across European markets.
Next steps (company-claimed)
Initial market rollout, clinician training and commercial footprint expansion; co-founder Dr. Tomas Baltrunas is quoted on scaling.
Platform (company-claimed)
A haptic, device-agnostic endovascular robotic platform for remote vascular procedures with tactile feedback, built to fit existing cath labs.
Applications (company-claimed)
Peripheral vascular, neurovascular and cardiovascular procedures.
Digital indeflator (company-claimed)
Recently unveiled a digital indeflator for angioplasty and stent deployment.
Verified record
- Verified deployments
- 2 deployments on file
- Active incidents
- None on file
Models (1)
View all models →Sentante on the deployment map
View the global map2 verified deployments across 2 regions, newest verified Jun 2024. Explore where Sentante's robots are operating, by place and type.
Relationships
Current leadership (1)
- Edvardas Satkauskas CEOsecondary-verified
Safety record
No incidents on record for Sentante.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Operator customers (1)
- Sentante2 deployments
Recent coverage
Sentante in third-party press
Peer companies
- DLR Institute of Robotics and Mechatronics6 models
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
Mentioned on (1)
Registry pages whose text names Sentante.
People (1)
Financial state
- Total funding
- $6.5M
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Funding rounds (1)
- Seed2023-12-01
$7M(reported)
Timeline
Every recorded move in Sentante’s history, most recent first: funding rounds, partnerships, acquisitions, supply-chain starts, key hires, and press.
Funding roundSeed funding round
2023-12-01Seed raising $6500000
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdAug 8, 2026
Added to the verified registry
- Deployment recordedJun 1, 2024
Sentante Endovascular Robotic Platform at United States
- Deployment recordedJun 1, 2024
Sentante Endovascular Robotic Platform at Germany, Europe
Sources (2)
Common questions
What is Sentante?
What does Sentante make?
Is Sentante publicly traded?
Who competes with Sentante?
Who is the CEO of Sentante?
How can I invest in Sentante?
Where is Sentante headquartered?
How much funding has Sentante raised?
Who owns Sentante?
Where does Sentante operate robots?
How many robots has Sentante deployed?
Is Sentante a top robotics company?
When was Sentante founded?
Is Sentante safe?
Methodology: Verified · 2 sources (no primary) · last reviewed 2026-10-13
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-10-13
Sources by quality tier
- 1
- secondary-trade-publication
- Trade publication
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Sentante.Peer companies
- DLR Institute of Robotics and Mechatronics6 models
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
In the press
Recent coverage mentioning Sentante from third-party publications. Automatically surfaced; not part of the verified registry record.
Sentante launches digital balloon inflation device for endovascular procedures
Sentante has unveiled a new precision-controlled digital indeflator—dubbed ‘Inflante’—that is designed to modernise balloon inflation, improving clinical control and procedural…
Sentante Secures €6 Million in New Funding to Revolutionize Endovascular Care
€6M seed round led by Practica Capital with EIC Fund participation; funds for clinical trial and commercial preparation
Machine-readable surfaces
- Markdown mirror: /companies/sentante.md
- RSS feed: /companies/sentante/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/b01ea9e1-7eb2-41ff-87ea-632d986c63bf
- Revision history: /companies/sentante/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- DLR Institute of Robotics and Mechatronics6 models
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
Video
Endovascular robotics for stroke or cardiac or peripheral and more. Deep diving into the haptic feedback world of Sentante Out of Lithuania comes an incredible
Sentante is more than a robotic solution - it’s the key to unlocking the fully digitalized cath lab of the future. By collecting real-time data on force, effort
Joe Mullings sits down with Edvardas Satkauskas, CEO of Sentante, to discuss the company’s groundbreaking work in robotic surgery and the future of MedTech.
Meet @Sentante_robot - the future of endovascular interventions🦾 Our fully robotic, teleoperated system offers a range of advantages that are set to transfor
With Sentante, we’ve created an interface where haptics finally make sense -bringing the feel of manual control into minimally invasive procedures. Sentante isn
Lorenzo Patrone shares his experience using Sentante, offering a brief user testimonial on how the robotic system is used and the value it provides.
Heat Index
Category contender75/100
A composite of competitive footprint, funding, press velocity, active partnerships, and supply-chain edges. Different from the Intelligence score below (which is per-form-factor productization). Non-robotics companies cap at 25.
Reality vs attention
Sentante draws attention at the 18th percentile but verifies reality at the 39th percentile among surgical robots. Hype Gap -21, 33rd widest among surgical robots.
6-month trend
Analysis
Clean safety record across 2 verified deployments. Deployment footprint remains limited relative to category peers.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Nov 7, 2026